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Abstract: Cancer is caused by the spatial and temporal accumulation of alterations in the genome of a given cell. This 
leads to the deregulation of key signalling pathways that play a pivotal role in the control of cell proliferation and cell fate. 
The p53 tumor suppressor gene is the most frequent target in genetic alterations in human cancers. The primary selective 
advantage of such mutations is the elimination of cellular wild type p53 activity. In addition, many evidences in vitro and 
in vivo have demonstrated that at least certain mutant forms of p53 may possess a gain of function, whereby they contrib-
ute positively to cancer progression. The fine mapping and deciphering of specific cancer phenotypes is taking advantage 
of molecular-profiling studies based on genome-wide approaches. Currently, high-throughput methods such as array-
based comparative genomic hybridization (CGH array), single nucleotide polymorphism array (SNP array), expression ar-
rays and ChIP-on-chip arrays are available to study mutant p53-associated alterations in human cancers. Here we will 
mainly focus on the integration of the results raised through oncogenomic platforms that aim to shed light on the molecu-
lar mechanisms underlying mutant p53 gain of function activities and to provide useful information on the molecular 
stratification of tumor patients. 
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INTRODUCTION 
  The p53 tumor suppressor protein is a sequence-specific 
transcription factor that is present in a latent form under 
normal conditions and becomes activated by a variety of 
stress signals, such as DNA damage, oncogene activation 
and improper mitogenic stimulation. p53 acts as a potent 
transcriptional activator through the binding as a homo-
tetramer to specific sequences, named p53 responsive ele-
ments (p53RE). Activated p53 modulates the expression of a 
large set of target genes involved in many cellular processes, 
including cell cycle arrest, DNA repair, apoptosis and senes-
cence. Growth arrest or cell death prevents damaged DNA 
from being replicated; thus suggesting a role for p53 in the 
maintenance of genome integrity [1-5]. p53 is a member of a 
family of proteins that has recently been established through 
the identification of p73, p63 and their related isoforms, all 
heavily involved in tumor suppression and development [6]. 
Half of all human cancers bears p53 mutations [7]. The most 
prevalent type of p53 alterations are missense mutations, 
often within the conserved DNA binding core domain of the 
protein [8,9]. In this area each residue has been found to be 
possibly mutated in human tumors, and the resulting proteins 
display a marked heterogeneity in terms of loss of structure 
and function. Several evidences demonstrate that a subset of 
p53 mutant proteins display gain of function activity [10], 
thereby actively participating to tumorigenesis (Fig. 1). 
Structural studies have allowed the classification of p53   
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mutant proteins in two major categories [11,12]: a) DNA 
contact defective (His273, Trp248), that includes those mu-
tants whose mutation impacts on the residues composing the 
DNA/protein interaction surface; b) defective structure 
(His175, His179), whose point mutation determines an im-
portant conformational alteration. At variance with the ob-
servations of several other tumor suppressor genes, cells 
with p53 mutations typically maintain expression of full-
length mutant protein, often at markedly elevated levels. 
This observation suggests the possibility that some mutant 
p53 proteins gain additional functions over the mere loss of 
wild-type TP53 activity. This hypothesis has been validated 
by a combination of in vitro and in vivo studies that show 
how mutant p53 proteins confer transformed properties to 
cell cultures and increased tumorigenicity in mice [13,14]. It 
has also been reported that conformational mutants, such as 
p53His175, but not DNA contact mutants (p53His273, 
p53Trp248), can increase cellular resistance to etoposide or 
can contribute to genomic instability by abrogating the mi-
totic spindle checkpoint, thereby facilitating the generation 
of aneuploid cells [15,16]. p53-/- mice develop a different 
spectrum of tumours compared to that of knock-in mice ex-
pressing various p53 hot spot mutants [15,17]. Indeed, mu-
tant p53 knock-in mice have a higher frequency of solid tu-
mours with high potential for metastasis, a feature not seen 
in knock-out animals. This peculiar spectrum of tumours is 
also observed in mice expressing one mutant p53 allele in a 
p53-null background, thus strongly suggesting a gain of 
function of mutant p53 proteins. Further analysis of mutant 
p53 knock-in models in mice defective in p63 and p73 sug-
gests that alteration in the activity of the entire p53 family is 
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Many questions regarding the molecular mechanisms at the 
basis of gain of function activities are still unsolved. 
  To date, we can depict the three following molecular 
scenarios to explain gain of function of mutant p53 proteins. 
(a) mutant p53 can bind to DNA through the association 
with DNA binding proteins and transcriptionally activate 
specific target genes using its functional transactivation do-
main (TAD). In support of this molecular mechanism, it has 
been reported that human tumor-derived p53 mutants, whose 
TAD was inactivated by site-directed mutagenesis, lost the 
ability to increase tumorigenicity in vitro and in vivo [8,13, 
19-21]; (b) recent work by Di Agostino et al. has shown that 
mutant p53 proteins physically interact in vivo with the tran-
scription factor NF-Y, whose DNA binding consensus are 
present in the regulatory regions of many key genes involved 
in the regulation of the cell cycle. Mutant p53 can be re-
cruited in vivo onto the promoter of NF-Y target genes, as a 
member of a large transcriptional complex that also includes 
histone acetyltransferases (HAT). Of note, mutant p53 fa-
vours the selective recruitment of HAT in response to DNA 
damage, thereby dictating the transcriptional activation of its 
target genes [22]. (c) mutant p53 binds to and sequesters 
proteins whose function is required for anti-tumor effects 
such as apoptosis or growth inhibition. Interestingly, it has 
been reported that human tumor-derived p53 mutants can 
associate with p73 and p63 and interfere with their transcrip-
tional activity and ability to induce apoptosis when co-
expressed in transient transfection assays (Fig. 2) [19,23-26]. 
  Many of the studies exploring the molecular mechanisms 
that underlie gain of function of mutant p53 proteins have 
mainly characterized the activities of p53 hot spot mutations. 
These mutants display an oncogenic potential by themselves, 
as demonstrated by transformation assays in vitro and knock-
in models in vivo. However, as mentioned above, mutations 
can occur within the entire DBD of the protein. The activity 
of a large number of p53 mutants has been analyzed by Kato 
et al. [27]. This analysis demonstrated that hot spot muta-
tions lost their transactivation activity completely, while the 
rest of the mutants retained some ability to transactivate tar-
get genes. In parallel to these observations, additional evi-
dences have shown that the clinical penetrance of p53 muta-
tions in cancer is strongly influenced by the genetic back-
ground of the individual [13,17,28] and by the presence of 
other cancer-associated somatic mutations [29]. 
  Since p53 mutations of the DBD are selected in cancer, it 
is reasonable to hypothesize that hot spot mutations are di-
rectly selected because they represent the driving force dur-
ing the neoplastic transformation. The remaining p53 muta-
tions are selected following a second mutational event that 
might be permissive for mutant p53 gain of function activi-
ties. Cell-type specificity for gain of function of mutant p53 
might explain why certain p53 mutants do not display any 
activity when exogenously overexpressed in cell systems 
different from those where the mutation was originated.  
p53 MUTATIONS AS PREDICTIVE/PROGNOSTIC 
MARKERS IN HUMAN CANCERS 
  Since the first description of a p53 mutation in human 
cancers in 1989, several thousands of papers have described 
clinical studies in which p53 has been tentatively linked to 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Wild type versus mutant p53 protein. In response to various types of cellular stress signals, wild-type p53 protein and its family 
members, p63 and p73, undergo different kinds of post-translational modifications, including phosphorylation and acetylation. These events 
cause p53 family members to stabilize and activate which results in growth arrest, apoptosis, senescence, and differentiation. However, cells 
carrying mutant p53 display increased cellular proliferation, genomic instability, chemoresistance, metastatization and invasion. 202    Current Genomics, 2008, Vol. 9, No. 3  Donzelli et al. 
the response to treatment (predictive power) or patient sur-
vival (prognostic power). The usefulness of these studies 
was questioned in terms of strategy (too few patients en-
rolled for correct statistical analysis) and methodology 
[30,31]. Indeed, the majority of the studies have relied on 
immunohistochemistry to assess p53 alterations. This ap-
proach is a poor surrogate for gene mutation detection since 
many mutations do not lead to protein accumulation, and 
also because an accumulation of wild type p53 might occur. 
Langerod et al. [32] have shown how IHC detects 50% of 
the p53 mutations identified through TTGE (temporal tem-
perature gradient gel electrophoresis). With the introduction 
of gene sequencing to precisely identify p53 mutations in 
cancer, it has been clearly defined that the presence of a p53 
mutation is correlated with a shorter survival or a poor re-
sponse to treatment in several cancers. Moreover, mutations 
within the DNA binding domain have been associated with a 
worst prognosis compared to that related to other p53 muta-
tions in breast cancer [33-36]. Now that the power of mutant 
p53 as a predictive/prognostic marker in breast cancer has 
been established, the complete characterization of mutant 
p53 contribution to tumorigenesis will require a combination 
of oncogenomic approaches, for example copy number ana- 
lyses, mutational studies and expression profiling (protein 
coding genes and microRNAs) on a large number of patients. 
MUTANT p53 AND CHROMOSOMAL INSTABILITY 
  The genome of cancer cells is thought to be unstable as 
they often harbour many chromosomal abnormalities. Due to 
the role of TP53 in maintaining genomic stability, its inacti-
vation profoundly impairs repair of DNA damage and could 
promote genomic alterations. Several research groups have 
reported a correlation between genomic instability and TP53 
mutations in breast cancer tissues. Using fluorescence in situ 
hybridization, Sigurdsson et al. [37] have shown that breast 
cancer cells with abnormal p53 display a higher copy num-
ber of chromosome 17 than cells without p53 staining. This 
points to a relationship between TP53 alterations and chro-
mosomal instability. Jain et al. [38] combined information 
on TP53 mutation status in breast carcinomas with their ge-
nomic complexity, as assessed by chromosomal comparative 
genomic hybridization (CGH), a technique capable of detect-
ing copy number alterations at chromosomal level [39]. They 
found that gain at 8q24 and loss at 5q15-5q21 are linked to 
mutant p53. Subsequently, Jong et al. [40] and Kleivi et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Molecular mechanisms underlying gain of function of mutant p53 protein.  
DNA binding. Mutant p53 protein can be recruited on the promoters of its target genes by the interaction with different transcription factors, 
as has been demonstrated for the transcription factor NF-Y in response to DNA damage (a), or by direct binding to specific consensus se-
quences that are still to be identified (b). Protein-protein interaction. (c) Mutant p53 protein binds to and sequesters proteins (p73 and p63) 
whose activities are closely connected to anti-tumoral effects such as apoptosis or growth inhibition.  Oncogenomic Approaches in Exploring Gain of Function of Mutant p53  Current Genomics, 2008, Vol. 9, No. 3    203 
[41] performed CGH analysis in relation to TP53 status on 
breast cancer specimens and confirmed a higher degree of 
abnormalities in patients carrying TP53 mutation, compared 
to those with wild type p53. These abnormalities appeared to 
cluster in certain chromosomal regions at significantly 
higher frequencies. Of note, the result of 8q gain associated 
with the TP53 mutated status was shared by all three studies. 
Identification of putative cancer-related genes that reside 
within these genomic loci, such as c-myc (at 8q24), and their 
potential interactions with mutant p53 might represent an 
exciting new area for breast cancer research.  
  Currently, high throughput methods such as array-based 
comparative genomic hybridization (CGH array) and single 
nucleotide polymorphism array (SNP array) are available to 
study mutant p53-associated alterations in a genome-wide 
fashion. Array-CGH is an established high-resolution me- 
thod to study the whole genome for chromosomal amplifica-
tions and deletions [42]. One limitation of the array-CGH 
method is its lack of genotype information. Subsequently, it 
fails to provide information about regions of LOH without 
copy number alteration (CNA) such as mitotic recombina-
tion or gene conversion events. Recently, high-density oli-
gonucleotide-based single polymorphism arrays (SNP ar-
rays) have been used to identify copy number and LOH of 
chromosomal regions. The advantage of a combined SNP-
CGH approach is the identification of allele specific 
gain/loss by SNP array and the robust copy number detection 
by array CGH. In addition to the copy number detection, 
SNP array would also lead to an increase in information 
about the genetic background of the analysed patients and 
about additional cancer-associated mutations. For example, 
this method would reveal the presence of specific SNP vari-
ants in components of p53-interacting pathways. The inte-
gration of these two platforms (CGH, SNP) with expression 
arrays will provide detailed and relevant information about 
the genomic alterations associated with  the mutated TP53 
status and about the consequences determined by these al-
terations at the expression level. It is still being debated as to 
whether copy number alterations lead to changes in gene 
expression. So far, few studies have indicated that a correla-
tion exists between chromosomal instability and gene ex-
pression in colorectal carcinoma and other cancer types 
[43,44]. Moreover, if particular associations between spe-
cific p53 mutations and other genomic alterations will be 
shown to be related to the clinical outcome of given tumors, 
it is highly possible that these combined analyses would re-
inforce the value of mutant p53 as a molecular biomarker in 
specific genetic contexts (Fig. 3).  
IDENTIFICATION OF mtp53-ASSOCIATED GENE-
EXPRESSION SIGNATURES 
  Two different approaches have been followed to identify 
mutant p53-associated gene-expression signatures: a) cell 
lines overexpressing different mutant forms of p53 have 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Oncogenomic approaches. Different kinds of oncogenomic approaches can be used to analyze genomic alterations in cell lines or 
tumor samples carrying mutant p53 proteins: CGH arrays, which allow the identification of chromosomal amplifications and deletions, and 
SNP arrays, by which it is possible to analyze the presence of LOH, copy number alterations, polymorphisms and cancer-associated muta-
tions.  204    Current Genomics, 2008, Vol. 9, No. 3  Donzelli et al. 
been generated to analyze the impact of mutant p53 on cell 
transcriptome;  b) tumor samples with characterized p53 
status (mutated or wild-type) have been examined by mi-
croarray analysis for their global gene expression. The latter 
has been compared with that of normal counterparts to de-
fine (mainly through hierarchical clustering or uninvariate 
analysis by SAM) clusters of genes associated with the mu-
tated status of p53. 
  A number of studies employed microarrays to evaluate 
global gene expression in H1299 lung cancer cells express-
ing p53-175H, p53-273H and p53-281G [45-47], p53-
deficient HCT116 colorectal cancer cells overexpressing 
p53-138P and p53-175H [48], osteosarcoma U2OS cells 
expressing p53-157F, p53-175H and p53-248Q [49], LNCaP 
prostate cancer cells expressing p53-245S, p53-248W, p53-
273C, p53-273H [50] as well as in Li Fraumeni syndrome-
derived fibroblasts expressing p53-175H [51] have been per-
formed. The main limitation of these studies is based on the 
fact that, except for the O’Farrell study [48], they failed to 
analyze the impact of wt p53 expression on the same cell 
system. For this reason, they were unable to assess whether 
some of the transcriptional modifications observed would 
have been found, to a different or opposite extent, upon ex-
pression of wild-type p53. Indeed, O’Farrell et al. report that 
the most obvious difference related to the ectopic expression 
of two diverse p53 mutants (R175H and A138P) is that 
R175H retained less wild-type transcriptional regulatory 
events than A138P. A long list of mutant p53-regulated 
genes has been obtained from microarray analyses, suggest-
ing the involvement of mutant p53 in several cellular proc-
esses ranging from transcriptional and translational regula-
tion, signal transduction, cell motility, invasion and metasta-
tization. This list obviously includes some of the genes pre-
viously characterized as mutant p53 targets. Importantly, all 
the identified genes provide evidence for the potential dis-
closure of new molecular targets and for substantial insights 
into the molecular mechanisms underlying gain of function 
activities of mutant p53.  
  In addition to the in vitro models of cell lines overex-
pressing p53 mutants, the impact of a mutated p53 on the 
transcriptome has also been evaluated through in vivo mi-
croarray analyses. As mentioned above, the mutational status 
of p53 is prognostic in many malignancies. In breast cancer, 
p53 mutations are associated with worse overall and disease-
free survival rates and have been implicated in resistance to 
anticancer therapies. Miller et al. [52] reported on a microar-
ray analysis performed on 251 primary invasive breast tu-
mors with known p53 status (58 carrying mutant p53 and 
193 wild-type). They found that tumors with mutated and 
wild-type p53 are distinguished by pervasive molecular dif-
ferences (mainly in genes controlling proliferation). They 
also identified a 32-gene expression signature (as optimal 
classifier) that distinguishes mutant versus wild-type p53 
tumors of different histological types. Furthermore, it also 
enables the prediction of the p53 status when tested on two 
publicly available microarray data sets (breast cancer [53], 
and liver cancer [54]) where p53 mutational status is known. 
The identified p53 signature predicts outcome better than 
p53 mutation status alone, also independently from the ther-
apy-specific data sets. 
  Despite the efficacy of these in vivo analyses in identify-
ing gene expression signatures associated with wild type or 
mutant p53, unfortunately these studies are unable to assess 
whether the characterized genes are really dependent on the 
presence of mutant p53 or whether they merely represent the 
result of a loss of wild-type p53 activity. The data sets de-
rived from microarray analyses on cell lines overexpressing 
p53 mutants, enclosing the putative genes responsible for 
gain of function, need to be matched with those derived from 
in vivo analyses to define which of the transcripts are truly 
expressed in cancer tissues carrying p53 mutation. Up until 
now few p53 mutations have been analyzed in vitro for their 
ability to transcriptionally affect gene expression. Further 
microarray analyses employing additional p53 mutants to be 
compared with those performed on tumor specimens with 
known p53 status might unveil important molecular details 
on the gain of function properties of the different mutant p53 
proteins present in human cancers. 
ChIP-CHIP AS A TOOL TO IDENTIFY mut-p53 
TRANSCRIPTIONAL SIGNATURES IN HUMAN 
CANCERS 
  Little is known about the mechanisms through which 
mutant p53 proteins, that have lost the ability to bind DNA 
in a sequence-specific manner, can achieve the specificity in 
gene regulation. Chromatin Immunoprecipitation experi-
ments have shown that mutant p53 can be found onto the 
regulatory regions of putative target genes, but despite ex-
tensive efforts, the identification of the specific DNA bind-
ing consensus of mutant p53 has not yet been found. It has 
been proposed that mutant p53 can be recruited to its puta-
tive target promoters through the physical interaction with 
sequence specific transcription factors whose specific DNA 
binding consensus are present on those regulatory regions. 
Sp1 and Ets, which were shown to cooperate with mutant 
p53 in transcriptional regulation [55-57], are paradigmatic of 
the proposed molecular mechanism. The notion that mutant 
p53 is recruited to transcriptional regulatory regions of pecu-
liar genes via interaction with other transcription factors is 
strongly supported by the work of Di Agostino et al. [22] 
which has shown the existence of a transcriptional competent 
protein complex involving mutant p53 and the transcription 
factor NF-Y. Along this transcriptional pathway mutant p53 
favours the recruitment of the coactivator p300 onto NF-Y 
target promoters, leading to the transcriptional activation of 
its target genes. Our group has recently also found that the 
transcription factors E2F-1 and p65 (RelA) are both con-
comitantly present with mutant p53 on the promoters of 
some putative target genes (G.F. and G.B. unpublished ob-
servations). 
  Due to the absence of a canonical consensus sequence for 
mutant p53, the only approach that seems truly promising for 
the precise deciphering of its transcriptional code is the use 
of whole-genome tiling arrays, designed to interrogate an 
entire genome in an unbiased fashion, for ChIP-chip analy-
sis. ChIP-chip (Chromatin Immunoprecipitation-chip) per-
mits a simultaneous analysis of the occupancy of a specific 
transcription factor on thousands of its target genes. Briefly, 
crosslinked chromatin (DNA/protein) complexes are ex-
tracted from the analyzed cell culture or from a tissue and 
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The chromatin fragments containing the transcription factor 
of interest are then immunoprecipitated using a specific anti-
body and the target sequences are subsequently identified 
through hybridization to DNA microarrays. At a high probe 
tiling resolution multiple overlapping probes may contain the 
actual transcription factor binding motif and thus enable a 
fine mapping of the binding site to a resolution of less than 
25 bp. Apart from the most recent generated tiling arrays, 
different kinds of microarrays have been generated for ChIP-
chip analysis. Initial studies were performed using slides 
carrying spotted oligonucleotides or PCR products from se-
lected predicted promoters. However these arrays are unable 
to interrogate the entire genome and are unable to address 
the possibility that transcription factors might bind to other 
locations. Recent studies using tiling arrays interrogating 
entire chromosomes show that a large fraction of in vivo 
binding sites are outside the predicted promoter regions of 
given genes. It has been shown that the binding locations of 
NFkB, cMyc, Sp1, p53, CREB are found within both coding 
and non-coding regions. More binding sites than those pre-
dicted were found and of those only a relatively small frac-
tion of the sites occurred in genomic regions that would typi-
cally be considered “promoters”. The use of tiling arrays in 
the study of mutant p53 transcriptional activity will over-
come the difficulties existing in the prediction of the binding 
sites for this oncogenic transcription factor. In addition, mu-
tant p53 has been reported to bind a wide range of DNA sec-
ondary structures. For example, mutant p53 was shown to 
preferentially bind matrix attachment regions (MARs) [58]. 
MARs are involved in the anchoring of chromatin fibres to 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). ChIP-chip approach. ChIP-chip technique allows for the simultaneous analysis of the presence of a specific transcription factor on 
the regulatory regions of thousands of its putative target genes. ChIP-chip analysis of chromatin immunoprecipitated with an antibody 
against p53 and subsequently re-immunoprecipitated with an antibody against a specific transcription factor (Re-ChIP), in a mutant p53 cel-
lular context, allows for the identification of a transcriptional protein complex that might control the activation or repression of a target gene. 
Two different types of slides can be used for the ChIP-chip analysis: dedicated slides containing oligonucleotide probes specific for different 
regions of known and putative target gene promoters; tiling slides containing oligonucleotide probes representing the entire genomic se-
quences. 206    Current Genomics, 2008, Vol. 9, No. 3  Donzelli et al. 
the nuclear matrix, generating chromatin domains that may 
enhance or repress transcription. Further studies from this 
group suggest that the binding to non-B DNA rather than a 
specific sequence represents the basis of the interaction be-
tween mutant p53 and MARs. If the binding of mutant p53 
to MARs leads to changes in chromatin accessibility and 
activity it becomes more necessary to identify the genes that 
will sense the effects of this non-sequence-specific binding. 
This information will likely be available after a hybridization 
of whole-genome tiling arrays with mutant p53-bound chro-
matin. 
  The ChIP-chip analysis of chromatin initially immuno-
precipitated with antibodies against mutant p53 and succes-
sively with antibodies directed to the various transcription 
factors that mediate mutant p53’s binding to its target genes 
(Re-ChIP) is likely to lead to the identification of subgroups 
of target genes controlled by different mutant p53-TF protein 
complexes (Fig. 4). 
CONCLUSIONS 
  Genome wide analyses are turning out to be powerful 
instruments in the molecular stratification of cancer patients. 
The complexity of the data raised through the oncogenomic 
approaches calls for the integration of multidisciplinary ex-
pertises and potentially accounts for the fine deciphering and 
molecular characterization of specific cancer patient pheno-
types. An understanding of the molecular events regulating 
and/or governed by gain of function mutant p53 proteins 
might lead to the disclosure of cancer signalling pathways to 
be tackled with novel anticancer therapies. 
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